Cough Hypersensitivity Syndrome Market Report 2026

The cough hypersensitivity syndrome market size has grown strongly in recent years. It will grow from $10.92 billion in 2025 to $11.65 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to high prevalence of asthma and gerd, limited understanding of cough hypersensitivity, reliance on symptomatic treatment, underdiagnosis of chronic cough conditions, hospital-based management.

The cough hypersensitivity syndrome market size is expected to see strong growth in the next few years. It will grow to $15.79 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancements in cough pathway research, development of novel antitussive drugs, increasing specialist referrals, improved diagnostic protocols, growing chronic respiratory disease burden. Major trends in the forecast period include growing focus on chronic cough diagnosis, increased use of targeted pharmacological therapies, rising awareness of cough reflex disorders, expansion of specialty respiratory clinics, integration of multidisciplinary treatment approaches.

The increasing prevalence of chronic respiratory diseases is expected to drive the growth of the cough hypersensitivity syndrome market in the coming years. Chronic respiratory diseases (CRDs) are a group of long-term conditions that affect the airways and lungs, resulting in ongoing breathing difficulties and a gradual decline in lung function. Treatment for cough hypersensitivity syndrome helps reduce discomfort and improve respiratory health, thereby enhancing the quality of life for patients with chronic respiratory diseases such as asthma. For example, in March 2025, according to the Australian Bureau of Statistics, an Australian-based government agency, in December 2024, there were 222 doctor-certified deaths due to COVID-19, an increase from 135 in October and 186 in November. Therefore, the growing prevalence of chronic respiratory diseases is contributing to the expansion of the cough hypersensitivity syndrome market.

Major companies operating in the cough hypersensitivity syndrome market are concentrating on advancing asthma treatment pipelines, including asthma rescue inhalers, to improve patient outcomes and overall quality of life. Asthma rescue inhalers are portable devices that deliver fast-acting medication to rapidly open the airways. These inhalers can help relieve sudden coughing episodes by temporarily reducing airway sensitivity and easing cough-related airway obstruction. For instance, in April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, partnered with Launch Therapeutics, a US-based clinical development company. The partnership is intended to accelerate the clinical research program for its ICS-SABA inhaler, TEV-248, which combines fluticasone propionate and albuterol sulfate and targets both adult and pediatric asthma patients. In addition, the initiative aims to reduce dependence on generic products.

In June 2023, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology company involved in manufacturing treatments for cough hypersensitivity syndrome, acquired Bellus Health Inc. for $2 billion. Through this acquisition, GSK seeks to expand its respiratory medication portfolio and strengthen its research and development, manufacturing, and commercialization capabilities. Bellus Health Inc. is a Canada-based biotechnology company focused on developing therapies for cough hypersensitivity syndrome.

Major companies operating in the cough hypersensitivity syndrome market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck and Co Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Wyeth Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Lupin Limited, Cadila Pharmaceuticals, Almirall S.A., Akorn Operating Company LLC, Kudco Ireland Ltd, Prestige Consumer Healthcare Inc., GMP Laboratories of America Inc., The Betty Mills Company, Acura Pharmaceuticals Inc.

North America was the largest region in the cough hypersensitivity syndrome market in 2025. The regions covered in the cough hypersensitivity syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cough hypersensitivity syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cough hypersensitivity syndrome market by increasing costs of imported active pharmaceutical ingredients, inhalation devices, and diagnostic tools. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported respiratory drugs, while Asia-Pacific faces higher formulation costs. These tariffs are increasing treatment expenses. However, they are also encouraging domestic drug manufacturing and localized respiratory therapy development.

The cough hypersensitivity syndrome market research report is one of a series of new reports that provides cough hypersensitivity syndrome market statistics, including cough hypersensitivity syndrome industry global market size, regional shares, competitors with a cough hypersensitivity syndrome market share, detailed cough hypersensitivity syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the cough hypersensitivity syndrome industry. This cough hypersensitivity syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cough hypersensitivity syndrome (CHS) is a medical condition marked by an heightened and abnormal sensitivity of the cough reflex to various triggers, frequently resulting in persistent and chronic coughing. It is commonly linked to conditions such as asthma, gastroesophageal reflux disease (GERD), and upper airway disorders.

The primary drug types used for managing cough hypersensitivity syndrome include inhaled corticosteroids, antitussive agents, short-acting beta-2 agonists, anticholinergics, proton pump inhibitors, antihistamines, and others. Inhaled corticosteroids (ICS) are a class of medications used to treat various respiratory conditions. The available routes of administration include oral, inhalation, and others, and these treatments are used by end users such as hospitals, specialty clinics, homecare settings, and other end users.

The cough hypersensitivity syndrome market consists of sales of cough suppressants, steam inhalers and humidifiers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.